Senate Bill No. 169, introduced by Senator Talbot, aims to amend and reenact R.S. 22:1028.5(D) and to enact new provisions under R.S. 22:1028.5(B)(4) and (F) concerning biomarker testing. The bill clarifies the criteria for establishing clinical utility in biomarker tests, ensuring that coverage for these tests is not contingent upon laboratory classifications or credentialing standards that do not relate to the test's performance. This change is intended to limit disruptions in patient care, such as the need for multiple biopsies or biospecimen samples, and to ensure that coverage is consistently applied.

Additionally, the bill addresses potential conflicts between existing laws regarding genetic testing for cancer screening and those related to biomarker testing for existing conditions, establishing that the provisions of this bill will take precedence in such cases. The legislation will become effective upon the governor's signature or after the designated time for gubernatorial action if not signed.

Statutes affected:
SB169 Original: 22:5(D)
SB169 Engrossed: 22:5(D)